Cancer Trials Ireland
- Country
- 🇮🇪Ireland
- Ownership
- Private
- Established
- 1996-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.cancertrials.ie
Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA Study
- Conditions
- Primary Peritoneal CarcinomaFallopian Tube CancerSerous Ovarian TumorEndometrioid Carcinoma Ovary
- Interventions
- Genetic: Somatic and Germline BRCA1/2 Testing
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Cancer Trials Ireland
- Target Recruit Count
- 200
- Registration Number
- NCT06274541
- Locations
- 🇮🇪
Mater Misericordiae University Hospital / Mater Private Hospital, Dublin, Leinster, Ireland
🇮🇪St James's Hospital, Dublin, Leinster, Ireland
🇮🇪Bon Secours, Cork, Munster, Ireland
Exploring the Impact of a Multi-modal Nutritional Intervention in Patients Undergoing Chemotherapy for Pancreatic Cancer (FEED Trial)
- Conditions
- Pancreatic Cancer
- Interventions
- Dietary Supplement: ControlDietary Supplement: Intervention
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Cancer Trials Ireland
- Target Recruit Count
- 70
- Registration Number
- NCT06149546
- Locations
- 🇮🇪
St Vincent's University Hospital, Dublin, Leinster, Ireland
Spine SABR - Dose-escalated Stereotactic Ablative Body Radiotherapy (SABR) for Solid Tumour Spine Metastases
- Conditions
- Solid Tumor Spine Metastases
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Cancer Trials Ireland
- Target Recruit Count
- 126
- Registration Number
- NCT06078813
- Locations
- 🇮🇪
Bon Secours/UPMC, Cork, Ireland
🇮🇪St Luke's Radiation Oncology Network (SLRON) at Beaumont Hospital, Dublin, Ireland
🇮🇪Beacon Hospital, Dublin, Ireland
Dose-Painted Intensity Modulated Radiotherapy Pancreas (DP-IMRT Pancreas)
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- Radiation: Dose-Painted Intensity Modulated Radiotherapy
- First Posted Date
- 2023-09-06
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Cancer Trials Ireland
- Target Recruit Count
- 49
- Registration Number
- NCT06024824
- Locations
- 🇮🇪
St Luke's Radiation Oncology Network (SLRON), Dublin, Ireland
🇮🇪St Vincent's University Hospital, Dublin, Ireland
Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)
- Conditions
- HER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2023-02-02
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Cancer Trials Ireland
- Target Recruit Count
- 11
- Registration Number
- NCT05710666
- Locations
- 🇮🇪
University Hospital Galway, Galway, Connaught, Ireland
🇮🇪Saint Vincent's University Hospital, Dublin, Leinster, Ireland
🇮🇪Beaumont Hospital, Dublin, Leinster, Ireland
PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Cancer Trials Ireland
- Target Recruit Count
- 22
- Registration Number
- NCT05518110
- Locations
- 🇮🇪
Mater Misericordiae University Hospital, Dublin, Ireland
🇮🇪St Vincent's University Hospital, Dublin, Ireland
Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2021-11-17
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Cancer Trials Ireland
- Target Recruit Count
- 54
- Registration Number
- NCT05123131
- Locations
- 🇩🇰
Aarhus University Hospital, Aarhus, Denmark
🇮🇪Beaumont Hospital, Dublin, Ireland
🇮🇪Mater Misericordiae University Hospital, Dublin, Ireland
Phase Ib of Cyclophosphamide, Pomalidomide, Dexamethasone and Daratumumab (CPD-DARA) in patients with relapsed/refractory multiple myeloma. (The CPD-DARA Study).
- Conditions
- Relapsed/ refractory multiple myeloma
- Interventions
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Cancer Trials Ireland
- Target Recruit Count
- 16
- Registration Number
- 2024-516945-37-00
- Locations
- 🇮🇪
University Hospital Galway, Galway, Ireland
🇮🇪Cork University Hospital, Cork, Ireland
🇮🇪Beaumont Hospital, Dublin 9, Ireland
Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer
- Conditions
- Advanced Pancreatic Cancer
- Interventions
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Cancer Trials Ireland
- Target Recruit Count
- 15
- Registration Number
- NCT04617067
- Locations
- 🇮🇪
Tallaght University Hospital, Dublin, Dublin 24, Ireland
🇮🇪St. Vincent's University Hospital, Dublin, Dublin 4, Ireland
🇮🇪Beaumont Hospital, Dublin, Dublin 9, Ireland
The COVID-IYON Study - Study Examining Data Pertaining to Clinical Outcomes and Organisational Responses to the 2020 SARS-CoV-2 Pandemic"
- Conditions
- COVID-19Cancer
- First Posted Date
- 2020-10-09
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- Cancer Trials Ireland
- Target Recruit Count
- 4
- Registration Number
- NCT04581070
- Locations
- 🇮🇪
Mater Misericordiae University Hospital, Dublin, Ireland
🇮🇪University Hospital Limerick, Limerick, Ireland
🇮🇪University Hospital Waterford, Waterford, Ireland